Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class A beta-lactamases are enzymes produced by bacteria that confer resistance to beta-lactam antibiotics, such as penicillins and cephalosporins, by hydrolyzing the characteristic four-membered beta-lactam ring of these drugs. These enzymes are among the most clinically significant mechanisms of antibiotic resistance in Gram-negative bacteria. They are serine-based enzymes, utilizing an active site serine (Ser70) for catalysis. Key structural motifs include Ser70xxLys, SDN, KTG, and ExxLN. The hydrolysis reaction proceeds via a two-step acylation-deacylation mechanism. They primarily hydrolyze penicillins but many variants can also degrade cephalosporins. Their broad substrate range underlies much clinical resistance to multiple classes of antibiotics. Beta-lactamase inhibitors such as clavulanic acid target class A enzymes but some variants show reduced sensitivity due to mutations.
Hydrolyzes beta-lactam ring, inactivating the antibiotic.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactamase (Class A).